arrow
U

Uday Popat

The University of Texas MD Anderson Cancer Center
H指数:67
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Daratumumab ± pomalidomide maintenance after salvage autologous transplantation in relapsed multiple myeloma: a phase 2 study

在复发多发性骨髓瘤中,自体移植后使用达鲁单抗±泊马利度胺进行维持治疗:一项2期研究

2026-09-260
OAAI
Outcomes of adult patients with Li-Fraumeni syndrome and myeloid neoplasms

Li-Fraumeni综合征合并髓系肿瘤的成人患者预后

Cancer
IF5.1
2026-09-180
OAAI
Donor-specific HLA mismatch: haploidentical versus 7/8 mismatched unrelated donor hematopoietic cell transplantation with PTCy

供者特异性HLA错配:单倍型与7/8位点错配无关供者造血干细胞移植联合PTCy

2026-06-170
PRE
Randomized trial of two fractionation schedules of myeloablative busulfan with fludarabine and cladribine in AML or MDS

随机对照试验:评估两种分次治疗方案下,在AML或MDS患者中使用大剂量白消安联合氟达拉滨和克拉屈滨的骨髓清除效果

2026-06-120
PRE
Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AML

新诊断FLT3突变AML患者使用阿扎胞苷、维奈克拉和吉列替尼的长期疗效

2026-05-280
OAAI
Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy

低强度治疗下急性髓系白血病中ASXL1突变的预后影响

Cancer
IF5.1
2026-05-060
OA
Evaluating the Impact of Fewer Frontline Intensive Chemotherapy Plus Venetoclax Consolidation Cycles on Outcomes in AML

评估减少一线强化疗联合Venetoclax巩固治疗周期对AML预后的影响

2026-03-040
OAAI
PTCy or ATG for Matched Transplantation in Myelofibrosis

为骨髓纤维化患者进行匹配移植的PTCy或ATG治疗方案

2026-02-230
OAAI
MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia

MECOM融合伙伴和骨髓原始细胞百分比影响MECOM重排急性髓系白血病患者预后

2025-09-220
PRE
Impact of discordant revised versus molecular international prognostic scoring system risk in myelodysplastic syndrome

不匹配的修订版与分子国际预后评分系统风险在骨髓增生异常综合征中的影响

Leukemia
IF13.4
2025-09-050
PRE
Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutation

新诊断的FLT3酪氨酸激酶域突变急性髓系白血病患者的结局:NPM1共突变的治疗意义

Cancer
IF5.1
2025-08-090
OAAI
Contemporary outcomes of octa-nonagenarians with newly diagnosed acute myeloid leukemia

新诊断急性髓系白血病八旬以上患者当代预后

Cancer
IF5.1
2025-08-070
OAAI
An ASTCT, CIBMTR, EBMT, and APBMT Consensus Statement Defining Response Criteria for Hematopoietic Cell Transplantation Associated Thrombotic Microangiopathy (TA-TMA) Directed Therapy

ASTCT、CIBMTR、EBMT和APBMT关于造血细胞移植相关血栓性微血管病(TA-TMA)导向治疗反应标准的共识声明

2025-06-010
OAAI
Clinico-Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies

临床基因组学探究继发性急性髓系白血病:对当代治疗的反应与结局

2025-02-082
PRE